Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.
Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T. Westhrin M, et al. Among authors: turesson i. Haematologica. 2015 Dec;100(12):e511-4. doi: 10.3324/haematol.2015.124511. Epub 2015 Aug 20. Haematologica. 2015. PMID: 26294726 Free PMC article. No abstract available.
Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.
Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, Waage A, Sundan A, Holien T. Olsen OE, et al. Among authors: turesson i. Cell Commun Signal. 2015 Jun 6;13:27. doi: 10.1186/s12964-015-0104-z. Cell Commun Signal. 2015. PMID: 26047946 Free PMC article.
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F. Gimsing P, et al. Among authors: turesson i. Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4. Lancet Oncol. 2010. PMID: 20863761 Clinical Trial.
Germline variants at SOHLH2 influence multiple myeloma risk.
Duran-Lozano L, Thorleifsson G, Lopez de Lapuente Portilla A, Niroula A, Went M, Thodberg M, Pertesi M, Ajore R, Cafaro C, Olason PI, Stefansdottir L, Bragi Walters G, Halldorsson GH, Turesson I, Kaiser MF, Weinhold N, Abildgaard N, Andersen NF, Mellqvist UH, Waage A, Juul-Vangsted A, Thorsteinsdottir U, Hansson M, Houlston R, Rafnar T, Stefansson K, Nilsson B. Duran-Lozano L, et al. Among authors: turesson i. Blood Cancer J. 2021 Apr 19;11(4):76. doi: 10.1038/s41408-021-00468-6. Blood Cancer J. 2021. PMID: 33875642 Free PMC article.
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group. Waage A, et al. Among authors: turesson i. Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6. Blood. 2010. PMID: 20448107 Free article. Clinical Trial.
Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk.
Duran-Lozano L, Thorleifsson G, Lopez de Lapuente Portilla A, Niroula A, Went M, Thodberg M, Pertesi M, Ajore R, Cafaro C, Olason PI, Stefansdottir L, Bragi Walters G, Halldorsson GH, Turesson I, Kaiser MF, Weinhold N, Abildgaard N, Andersen NF, Mellqvist UH, Waage A, Juul-Vangsted A, Thorsteinsdottir U, Hansson M, Houlston R, Rafnar T, Stefansson K, Nilsson B. Duran-Lozano L, et al. Among authors: turesson i. Blood Cancer J. 2021 Nov 16;11(11):181. doi: 10.1038/s41408-021-00575-4. Blood Cancer J. 2021. PMID: 34782614 Free PMC article. No abstract available.
Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.
Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Børset M, Waage A; Nordic Myeloma Study Group. Seidel C, et al. Among authors: turesson i. Br J Haematol. 2002 Dec;119(3):672-6. doi: 10.1046/j.1365-2141.2002.03898.x. Br J Haematol. 2002. PMID: 12437643 Free article. Clinical Trial.
292 results